Splenic neuromodulation as monotherapy and in combination with biologic or targeted synthetic DMARDs for difficult-to-treat rheumatoid arthritis (ConsiderRAte): a randomised, sham-controlled, early feasibility trial.

Tas SW, Christiaans J, Boumans MJH, Koopman FA, Pickrell P, Goddard DH, Kivitz A, Patel-Banker M, Chu CQ, Lee E, Wickersham P, Alli VV, Faulkenberry TL, Jenkins M, Winder J, Luyer MDP, Barnett C, Famm K, Irwin E, Kwong K, Scribner LL, Milliken PH, Raji O, Rall K, Sokal DM, Whiteman H, Mahmood A, Vervoordeldonk MJ, Gupta I, Abdulai RM, Broen JCA

Open source

DOI: 10.1016/j.eclinm.2026.104133
Published: 2026 Aug
Container: EClinicalMedicine
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1016/j.eclinm.2026.104133,
  title = {Splenic neuromodulation as monotherapy and in combination with biologic or targeted synthetic DMARDs for difficult-to-treat rheumatoid arthritis (ConsiderRAte): a randomised, sham-controlled, early feasibility trial.},
  author = {Tas SW and Christiaans J and Boumans MJH and Koopman FA and Pickrell P and Goddard DH and Kivitz A and Patel-Banker M and Chu CQ and Lee E and Wickersham P and Alli VV and Faulkenberry TL and Jenkins M and Winder J and Luyer MDP and Barnett C and Famm K and Irwin E and Kwong K and Scribner LL and Milliken PH and Raji O and Rall K and Sokal DM and Whiteman H and Mahmood A and Vervoordeldonk MJ and Gupta I and Abdulai RM and Broen JCA},
  year = {2026},
  journal = {EClinicalMedicine},
  doi = {10.1016/j.eclinm.2026.104133},
  url = {https://doi.org/10.1016/j.eclinm.2026.104133}
}

RIS

TY  - JOUR
TI  - Splenic neuromodulation as monotherapy and in combination with biologic or targeted synthetic DMARDs for difficult-to-treat rheumatoid arthritis (ConsiderRAte): a randomised, sham-controlled, early feasibility trial.
AU  - Tas SW
AU  - Christiaans J
AU  - Boumans MJH
AU  - Koopman FA
AU  - Pickrell P
AU  - Goddard DH
AU  - Kivitz A
AU  - Patel-Banker M
AU  - Chu CQ
AU  - Lee E
AU  - Wickersham P
AU  - Alli VV
AU  - Faulkenberry TL
AU  - Jenkins M
AU  - Winder J
AU  - Luyer MDP
AU  - Barnett C
AU  - Famm K
AU  - Irwin E
AU  - Kwong K
AU  - Scribner LL
AU  - Milliken PH
AU  - Raji O
AU  - Rall K
AU  - Sokal DM
AU  - Whiteman H
AU  - Mahmood A
AU  - Vervoordeldonk MJ
AU  - Gupta I
AU  - Abdulai RM
AU  - Broen JCA
PY  - 2026
JO  - EClinicalMedicine
DO  - 10.1016/j.eclinm.2026.104133
UR  - https://doi.org/10.1016/j.eclinm.2026.104133
ER  -

APA

SW, T., J, C., MJH, B., FA, K., P, P., DH, G., A, K., M, P., CQ, C., E, L., P, W., VV, A., TL, F., M, J., J, W., MDP, L., C, B., K, F., E, I., K, K., LL, S., PH, M., O, R., K, R., DM, S., H, W., A, M., MJ, V., I, G., RM, A., & JCA, B. (2026). Splenic neuromodulation as monotherapy and in combination with biologic or targeted synthetic DMARDs for difficult-to-treat rheumatoid arthritis (ConsiderRAte): a randomised, sham-controlled, early feasibility trial.. EClinicalMedicine. https://doi.org/10.1016/j.eclinm.2026.104133

Source records

pubmed · retrieved 2026-09-26T03:26:02.311Z